Covalon Technologies (COV) Planet MicroCap Showcase: TORONTO 2025 summary

Company overview and mission

• Focuses on accelerating patient healing and reducing complications such as infections and skin tears, with a 20-year history and recent annual revenue of CAD 33 million and Adjusted EBITDA of CAD 4 million.

• Operates primarily in wound care and vascular access, with wound care representing over half of revenue and a strong U.S. market presence.

• Emphasizes a mission-driven approach, aiming to improve patient outcomes and experiences.

Leadership and strategic focus

• CEO brings extensive medtech experience from large multinationals, applying lessons in prioritization and focus to streamline operations.

• Shifted company strategy to concentrate on core U.S. product lines, resulting in notable growth.

• Maintains a pipeline of future opportunities to ensure adaptability amid changing market conditions.

Business segments and growth

• Wound care business uses an OEM model with a small customer base, fueling EBITDA through low SG&A and targeting a $150–$200 million direct market within a $10 billion space.

• Vascular access business follows a direct sales model, primarily serving hospitals, and has achieved a high CAGR in recent years.

• Both segments provide optionality and resilience for future growth.